-
The HIV community has been asking since 1982: "How might we go about encouraging condom use in discordant couples?" On the whole, our efforts have been a disappointing failure.
-
If your facility provides comprehensive sexually transmitted disease care for men who have sex with men (MSM), be sure to incorporate new guidance from the Centers for Disease Control and Prevention (CDC) regarding gonorrhea and chlamydia testing.
-
Women who want a permanent form of birth control now have a new option. The Food and Drug Administration (FDA) has approved the Adiana permanent contraception system, manufactured by Hologic of Bedford, MA.
-
Findings from new research may aid clinicians in identifying women who are likely to gain weight while using depot medroxyprogesterone acetate (DMPA, Depo Provera). Research indicates that DMPA users whose weight increased by 5% within the first six months of use are at risk of continued, excessive weight gain.
-
With the wide array of birth control options available today, are adolescents still relying on coitus interruptus? Results of a 2009 study indicate that clinicians should not consider use of contraceptive withdrawal infrequent among teens.
-
After taking the necessary diagnostic steps, the results are clear: The patient sitting in front of you needs to be treated for bacterial vaginosis (BV). The most common vaginal infection in women of childbearing age, women with BV may present with a white or gray discharge, odor, pain, or burning during urination. Symptoms aren't always present, though. More than 50% of women with BV may be asymptomatic.
-
Two new programs have been announced by Merck & Co. to help confirm patients' insurance coverage and address providers' reimbursement concerns regarding Gardasil, the quadrivalent human papillomavirus (HPV) vaccine.
-
A population-based telephone survey was conducted among residents < 20 years of age in Antelope Valley, CA, from 2000 through 2006. During this period, 459 evaluable cases of herpes zoster among persons < 20 years of age were reported.
-
Patients eligible for EFV-based haart (EFV plus two nucleoside RT inhibitors) were randomized to EFV in an escalating dose over two weeks vs. standard 600 mg/d dosing. NPAEs and sleep quality were assessed by questionnaires over the first 30 days of therapy.
-
A prospective study of congenital cytomegalovirus (CMV) infection was conducted in two hospitals in São Paulo, Brazil, from 2003 to 2007 in a maternal population with high seroprevalence to CMV.
